Paul Bhatt

Paul Bhatt leads epigenetic drug development programs in oncology with expertise in HDAC inhibitors and BET bromodomain inhibitors. His industry research characterized the activity of vorinostat and romidepsin in hematologic malignancies and contributed to their FDA approval. He has developed next-generation HDAC inhibitors with improved selectivity profiles and studied their combination with immunotherapy. His work on epigenetic priming to enhance chemotherapy and immunotherapy response spans multiple tumor types.